about
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceu...
Read More
5.97
-0.03
(-0.50%)
480.1K
XNAS Volume
XNAS 11 Jul, 2025 5:30 PM (EDT)
Medium Financial Strength
Expensive Valuation
Technically Neutral
Expensive Performer
These stocks are with medium quality and mid-range technical aspects. However, their financials make them little expensive so choose the right moment to buy them.
View Similar
Embed DVM
Immatics N.V Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..